If you are taking Cimzia® for an inflammatory disease, and you are newly or may be pregnant or hoping to be pregnant soon, you might qualify for the CHERISH clinical research study.
Pregnancy can affect the symptoms of a woman’s chronic inflammatory condition as well as her response to treatment. CHERISH is a clinical research study that will measure certolizumab pegol (Cimzia®) plasma levels in the blood over the course of pregnancy and after delivery.
You may be eligible to participate in this study if you are 18 years of age or older at the time you join the study, and you:
- Have been pregnant for 10 weeks or less at the time of enrolling in the study.
- Are currently being treated with Cimzia® for a chronic inflammatory condition and have been on a stable maintenance dose for at least 12 weeks at the time you join the study.
- Plan to continue receiving Cimzia® throughout your pregnancy and for at least 12 weeks after your delivery.
Additional criteria apply.
Study participants will continue to obtain and administer their own supply of commercially available Cimzia® under the care of their physician.